Trial Profile
Phase II Study of BKM120 in Men With Metastatic Castration-Resistant Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary) ; Enzalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Aug 2017 According to results published in the European Journal of Cancer, concurrent buparlisib and enzalutamide at 160 mg once daily was permitted through a protocol amendment in order to test the efficacy of combined pathway inhibition in men with mCRPC progressing on enzalutamide, the use of concurrent enzalutamide was not randomized but rather offered to patients progressing on enzalutamide at entry.
- 01 Aug 2017 Results published in the European Journal of Cancer.
- 22 Feb 2017 Status changed from active, no longer recruiting to discontinued.